AJANTPHARM Ajanta Pharma Q4 FY26 results (Jan–Mar 2026) and concall
Ajanta Pharma reported a strong Q4 and FY26, achieving significant milestones with revenue exceeding ₹5,000 crores and net profit surpassing ₹1,000 crores. The US Generics and India businesses were key growth drivers, while the Asia Branded Generics segment faced headwinds due to geopolitical issues. The company provided FY27 guidance for high-teen revenue growth and an EBITDA margin of 27% (+/- 1%), factoring in continued investments and rising costs.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 21.5%, net profit up 18.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,187 | 1,146 | 1,170 | 1,303 | 1,354 +14% | 1,375 +20% | 1,422 +22% |
| EBITDA | 311 | 321 | 297 | 351 | 328 +5% | 382 +19% | 333 +12% |
| Net profit | 216 | 233 | 225 | 255 | 260 +20% | 274 +18% | 267 +19% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
